Corrigendum to “Long-term efficacy and safety of single-dose omalizumab in treating acute spontaneous urticaria” [Allerg Med 4 (2025) 100049]. // Allergy Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2949913526000194?dgcid=rss_sd_all
Corrigendum to “Long-term efficacy and safety of single-dose omalizumab in treating acute spontaneous urticaria” [Allerg Med 4 (2025) 100049]. Allergy Medicine. https://www.sciencedirect.com/science/article/pii/S2949913526000194?dgcid=rss_sd_all
“Corrigendum to “Long-term efficacy and safety of single-dose omalizumab in treating acute spontaneous urticaria” [Allerg Med 4 (2025) 100049].” Allergy Medicine.
@article{article34196,
title = {Corrigendum to “Long-term efficacy and safety of single-dose omalizumab in treating acute spontaneous urticaria” [Allerg Med 4 (2025) 100049]},
journal = {Allergy Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2949913526000194?dgcid=rss_sd_all}
}
Publication date: November–December 2026 Source: Acta Otorrinolaringologica (English Edition), Volume 77, Issue 6 Author(s): Daniel Álvarez de Castro, Sandra Pérez de la Iglesia, Miguel Ramírez Verdyguer, Francisco José Manzano Gómez